PATH SHAREHOLDER ALERT: The Law Firm Of Wohl & Fruchter Is Investigating The Acquisition Of NuPathe, Inc. By Endo Health Solutions Inc.

The law firm of Wohl & Fruchter LLP is investigating the acquisition of NuPathe, Inc. (NuPathe) (Nasdaq:PATH) by Endo Health Solutions Inc. (Endo).

On December 16, 2013, NuPathe announced that Endo has agreed to commence a tender offer to purchase all of the outstanding shares of NuPathe common stock at a price of $2.85 per share, plus contractual rights to receive up to an additional $3.15 per share in contingent cash consideration payments, which will be payable upon achieving certain net sales milestones of Zecuity®, NuPathe’s FDA-approved migraine treatment. Zecuity® is the first and only FDA-approved prescription migraine patch.

Wohl & Fruchter’s investigation concerns the adequacy of the consideration being paid to PATH shareholders given the commercial potential of Zecuity®, and whether the board of directors of Nupathe breached their fiduciary duties to PATH shareholders by failing to adequately shop the company.

Persons with relevant information, and PATH shareholders with questions about this investigation, are invited to contact our Firm by calling 866.833.6245, or contacting the attorney below.

Additional information is available at  http://www.wohlfruchter.com/cases/path.

About Wohl & Fruchter

Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and other fiduciary breaches by corporate managers, as well as other complex litigation matters. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.

This release may be deemed to constitute attorney advertising.

Copyright Business Wire 2010

If you liked this article you might like

Teva (TEVA) Acquires NuPathe (PATH) for $144 Million

NuPathe Picks Teva as Merger Partner

Why NuPathe Inc. (PATH) Is Up Today

Nupathe's Failure to Launch Leads to Modest Takeover

5 Stocks Under $10 Set to Soar